Ionis Pharmaceuticals Inc
IONS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000874015
In the last 90 days, Ionis Pharmaceuticals Inc insiders filed 1 open-market purchase and 7 sales; 530 institutions reported holding it in 13F filings for Q2 2026, worth $15.2B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysLast 90 days, $1.06M in total
- 1
- Insider sellsLast 90 days, $6.35M in total
- 7
- 13F holdersQ2 2026, +20 vs. previous quarter
- 530
- 13F valueReported value at the end of Q2 2026
- $15.2B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding IONS, Q2 2026
1 superinvestor reports holding Ionis Pharmaceuticals Inc on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Ionis Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 (view filing)4:42 PM ET | Jul 30-31 | 1 day | Hayden Michael RDirector | PPurchase | +20.0K | $52.94 | +$1.06M | +500.0%24.0K after | 2 lots |
| Jul 9, 2026 (view filing)7:26 PM ET | Jul 7 | 2 days | Bennett C FrankEVP, Chief Scientific Officer | SSale | −5.54K | $83.58 | −$462.7K | −6.9%75.0K after | 10b5-1 |
| Jul 9, 2026 (view filing)7:26 PM ET | Jul 7 | 2 days | Bennett C FrankEVP, Chief Scientific Officer | SSale | −15.0K | $85.46 | −$1.28M | −100.0%0 after | 10b5-1 |
| Jul 9, 2026 (view filing)6:07 PM ET | Jul 7 | 2 days | Diaz Allene M.Director | SSale | −10.1K | $85.42 | −$863.6K | −72.6%3.81K after | 10b5-1 |
| Jul 9, 2026 (view filing)6:07 PM ET | Jul 7 | 2 days | Kordasiewicz Holly B.EVP, Chief Development Officer | SSale | −362 | $84.30 | −$30.5K | −1.6%22.1K after | 10b5-1 |
| Jul 6, 2026 (view filing)6:49 PM ET | Jul 1 | 5 days | Klein Joseph IIIDirector | SSale | −11.5K | $79.04 | −$910.4K | −51.1%11.0K after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Baroldi JosephEVP, Chief Business Officer | SSale | −5.63K | $80.16 | −$451.7K | −54.7%4.67K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | O'Neil Patrick R.EVP CLO & General Counsel | SSale | −3.07K | $80.00 | −$245.5K | −4.8%61.5K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Schneider EugeneEVP, Chf Clinical Develop Ofcr | SSale | −26.0K | $81.05 | −$2.11M | −25.2%77.1K after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 24-26 | 2 days | Monia Brett PChief Executive Officer | SSale | −85.6K | $79.70 | −$6.83M | −25.9%245.6K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Ionis Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 24,631,956 | $1.96B | 0.09% | +75,319+0.3% | Added |
| Capital World Investors | 21,669,226 | $1.72B | 0.20% | +482,857+2.3% | Added |
| BlackRock, Inc. | 10,704,660 | $866.5M | 0.01% | +262,184+2.5% | Added |
| Wellington Management Group LLP | 7,651,415 | $624.6M | 0.11% | +1,259,599+19.7% | Added |
| Vanguard Portfolio Management LLC | 7,859,529 | $623.2M | 0.03% | +50,627+0.6% | Added |
| Vanguard Capital Management LLC | 7,211,497 | $571.8M | 0.01% | +93,167+1.3% | Added |
| Two Sigma Investments, LP | 6,252,342 | $495.7M | 0.37% | +394,713+6.7% | Added |
| Royal Bank of Canada | 6,182,479 | $490.4M | 0.08% | +2,380,664+62.6% | Added |
| State Street Corp | 4,334,848 | $367.1M | 0.01% | +339,284+8.5% | Added |
| T. Rowe Price Investment Management, Inc. | 3,959,372 | $313.9M | 0.21% | −2,199,655−35.7% | Reduced |